According to our established cut-off points, serum NF-L levels above 196 pg/mL in breast cancer patients undergoing therapy indicate the presence of low-grade neuropathy, while values above 218 pg/mL may indicate advanced CIPN. The gene discussed is NEFL; the disease is neuropathy.